Biblio

Author Title [ Type(Asc)] Year
Filters: First Letter Of Title is V  [Clear All Filters]
Journal Article
Wu K, Feng J, Xiu Y, Li Z, Lin Z, Zhao H, Zeng H, Xia W, Yu L, Xu B. Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients. Int Immunopharmacol. 2020;80:106122.
Xu W, Moon A, Chetty N, Lourie R, Shannon C. Vulvar yolk sac tumor diagnosed during pregnancy, with recurrence during subsequent second pregnancy. Gynecol Oncol Rep. 2015;12:67-71.
Preston M, Richards A. Vulvar and Vaginal Graft Versus Host Disease After Allogeneic Stem Cell Transplant-A Systematic Review. J Low Genit Tract Dis. 2023;27(3):266-274.
Sheng S, Bernardo M, Dzinic SH, Chen K, Sakr WA. The vulnerable primed cancer stem cells in disguise: demystifying the role of Maspin. Cancer Metastasis Rev. 2022.
Ishida Y, Kawakami H, Kitajima H, Nishiyama A, Sasai Y, Inoue H, Muguruma K. Vulnerability of Purkinje Cells Generated from Spinocerebellar Ataxia Type 6 Patient-Derived iPSCs. Cell Rep. 2016;17(6):1482-1490.
Meyers LM, Krawic C, Luczak MW, Zhitkovich A. Vulnerability of HIF1α and HIF2α to damage by proteotoxic stressors. Toxicol Appl Pharmacol. 2022:116041.
Kang Y-J, Clement EM, Park I-H, Greenfield LJohn, Smith BN, Lee S-H. Vulnerability of cholecystokinin-expressing GABAergic interneurons in the unilateral intrahippocampal kainate mouse model of temporal lobe epilepsy. Exp Neurol. 2021:113724.
Lee SKyun, Kim YSeon, Bae GHo, Lee HYoung, Bae Y-S. VU0155069 inhibits inflammasome activation independent of phospholipase D1 activity. Sci Rep. 2019;9(1):14349.
Chen D, Tan C, Ding P, Luo L, Zhu J, Jiang X, Ou Z, Ding X, Lan T, Zhu Y, et al. VThunter: a database for single-cell screening of virus target cells in the animal kingdom. Nucleic Acids Res. 2021.
Nicholls H. VSELs: is ideology overtaking science?. Cell Stem Cell. 2013;13(2):143-4.
Li Y, Cui C, Xie F, Kiełbasa S, Mei H, van Dinther M, van Dam H, Bauer A, Zhang L, Dijke PTen. VprBP mitigates TGF-β and Activin signaling by promoting Smurf1-mediated type I receptor degradation. J Mol Cell Biol. 2019.
Guo W, Tsujimura K, I MOtsuka, Irie K, Igarashi K, Nakashima K, Zhao X. VPA Alleviates Neurological Deficits and Restores Gene Expression in a Mouse Model of Rett Syndrome. PLoS One. 2014;9(6):e100215.
Tutak I, Özdil B, Uysal A. Voxtalisib and low intensity pulsed ultrasound combinatorial effect on glioblastoma multiforme cancer stem cells via PI3K/AKT/mTOR. Pathol Res Pract. 2022;239:154145.
Awan H, Balasubramaniam S, Odysseos A. A Voxel Model to Decipher the Role of Molecular Communication in the Growth of Glioblastoma Multiforme. IEEE Trans Nanobioscience. 2021;PP.
Xu S, De Veirman K, Vanderkerken K, Van Riet I. Vorinostat-induced bone loss might be related to the drug toxicity. Bone. 2013.
Zierfuss B, Weinhofer I, Kühl J-S, Köhler W, Bley A, Zauner K, Binder J, Martinović K, Seiser C, Hertzberg C, et al. Vorinostat in the acute neuroinflammatory form of X-linked adrenoleukodystrophy. Ann Clin Transl Neurol. 2020.
Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, et al. Vorinostat Combined with High-Dose Gemcitabine, Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015.
Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, et al. Vorinostat combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-term Study Outcomes. Transplant Cell Ther. 2022.
Thekkudan SFrancis, Kumar P, Nityanand S. Voriconazole-induced skeletal fluorosis in an allogenic hematopoietic stem cell transplant recipient. Ann Hematol. 2016.
Bucknor MD, Gross AJ, Link TM. Voriconazole-induced periostitis in two post-transplant patients. J Radiol Case Rep. 2013;7(8):10-7.
Jørgensen KJuhl, Gøtzsche PC, Dalbøge CS, Johansen HKrogh. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. Cochrane Database Syst Rev. 2014;2:CD004707.
Lindsay J, Krantz EM, Morris J, Sweet A, Tverdek F, Joshi A, Yeh R, Hill JA, Greenwood M, Chen SC-A, et al. Voriconazole in hematopoietic stem cell transplantation and cellular therapies: Real-world usage and therapeutic level attainment at a major transplant center. Transplant Cell Ther. 2022.
Pagliari MTeresa, Rosendaal FR, Ahmadinejad M, Badiee Z, Baghaipour M-R, Baronciani L, Hidalgo OBenítez, Bodó I, Budde U, Castaman G, et al. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study. J Thromb Haemost. 2022.
Pagliari MTeresa, Budde U, Baronciani L, Eshghi P, Ahmadinejad M, Badiee Z, Baghaipour M-R, Hidalgo OBenítez, Biguzzi E, Bodó I, et al. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. J Thromb Haemost. 2023.
Leigh ND, Sessa S, Dragalzew AC, Payzin-Dogru D, Sousa JF, Aggouras AN, Johnson K, Dunlap GS, Haas BJ, Levin M, et al. von Willebrand factor D and EGF domains is an evolutionarily conserved and required feature of blastemas capable of multitissue appendage regeneration. Evol Dev. 2020.

Pages